Aldeyra Therapeutics Company Profile (NASDAQ:ALDX)

About Aldeyra Therapeutics (NASDAQ:ALDX)

Aldeyra Therapeutics logoAldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ALDX
  • CUSIP: N/A
  • Web: www.aldeyra.com
Capitalization:
  • Market Cap: $28.73 million
  • Outstanding Shares: 6,245,000
Average Prices:
  • 50 Day Moving Avg: $4.49
  • 200 Day Moving Avg: $5.06
  • 52 Week Range: $3.80 - $8.19
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.34
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.85 per share
  • Price / Book: 2.49
Profitability:
  • EBIDTA: ($18,790,000.00)
  • Return on Equity: -73.19%
  • Return on Assets: -64.74%
Debt:
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 11.07%
  • Quick Ratio: 11.07%
Misc:
  • Average Volume: 81,456 shs.
  • Beta: 0.41
  • Short Ratio: 1.73
 

Frequently Asked Questions for Aldeyra Therapeutics (NASDAQ:ALDX)

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics Inc (NASDAQ:ALDX) issued its quarterly earnings data on Monday, May, 15th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.04. View Aldeyra Therapeutics' Earnings History.

Where is Aldeyra Therapeutics' stock going? Where will Aldeyra Therapeutics' stock price be in 2017?

4 analysts have issued twelve-month price targets for Aldeyra Therapeutics' shares. Their forecasts range from $12.00 to $20.00. On average, they anticipate Aldeyra Therapeutics' stock price to reach $16.50 in the next year. View Analyst Ratings for Aldeyra Therapeutics.

What are analysts saying about Aldeyra Therapeutics stock?

Here are some recent quotes from research analysts about Aldeyra Therapeutics stock:

  • 1. Cowen and Company analysts commented, "On its 4Q call, ALDX announced the Feb start of the planned ADX-102 Ph2b allergic." (3/31/2017)
  • 2. According to Zacks Investment Research, "Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. " (3/24/2017)

Who are some of Aldeyra Therapeutics' key competitors?

Who owns Aldeyra Therapeutics stock?

Aldeyra Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (46.20%), FMR LLC (27.31%), AWM Investment Company Inc. (14.61%), Sphera Funds Management LTD. (10.70%), Vanguard Group Inc. (4.73%) and Boxer Capital LLC (4.66%). Company insiders that own Aldeyra Therapeutics stock include Martin Joseph Joyce, Perceptive Advisors Llc, Stephen J Tulipano and Todd C Brady. View Institutional Ownership Trends for Aldeyra Therapeutics.

Who sold Aldeyra Therapeutics stock? Who is selling Aldeyra Therapeutics stock?

Aldeyra Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC. View Insider Buying and Selling for Aldeyra Therapeutics.

Who bought Aldeyra Therapeutics stock? Who is buying Aldeyra Therapeutics stock?

Aldeyra Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Sphera Funds Management LTD., Sabby Management LLC, Vanguard Group Inc., Hikari Power Ltd, Renaissance Technologies LLC and Geode Capital Management LLC. Company insiders that have bought Aldeyra Therapeutics stock in the last two years include Martin Joseph Joyce, Perceptive Advisors Llc, Stephen J Tulipano and Todd C Brady. View Insider Buying and Selling for Aldeyra Therapeutics.

How do I buy Aldeyra Therapeutics stock?

Shares of Aldeyra Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Aldeyra Therapeutics stock cost?

One share of Aldeyra Therapeutics stock can currently be purchased for approximately $4.60.

Analyst Ratings

Consensus Ratings for Aldeyra Therapeutics (NASDAQ:ALDX) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.50 (258.70% upside)

Analysts' Ratings History for Aldeyra Therapeutics (NASDAQ:ALDX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/1/2017HC WainwrightSet Price TargetBuy$18.00HighView Rating Details
3/31/2017Canaccord GenuityReiterated RatingBuy$15.00 -> $12.00LowView Rating Details
3/31/2017Cowen and CompanyReiterated RatingBuy$20.00LowView Rating Details
7/1/2016Stifel NicolausInitiated CoverageBuy$16.00N/AView Rating Details
2/29/2016Janney Montgomery ScottReiterated RatingBuyN/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Aldeyra Therapeutics (NASDAQ:ALDX)
Earnings by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)
Earnings History by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1 2017($0.33)($0.37)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.66)($0.36)ViewN/AView Earnings Details
11/14/2016Q316($0.39)($0.38)ViewN/AView Earnings Details
8/10/2016Q216($0.44)($0.41)ViewListenView Earnings Details
5/9/2016Q116($0.50)($0.51)ViewN/AView Earnings Details
11/12/2015Q315($0.29)($0.35)ViewListenView Earnings Details
8/11/2015Q215($0.35)($0.27)ViewListenView Earnings Details
5/13/2015Q115($0.39)($0.32)ViewListenView Earnings Details
4/14/2015($0.39)($0.31)ViewN/AView Earnings Details
11/10/2014Q314($0.32)($0.36)ViewN/AView Earnings Details
8/4/2014Q214($0.53)($1.56)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aldeyra Therapeutics (NASDAQ:ALDX)
Current Year EPS Consensus Estimate: $-1.66 EPS
Next Year EPS Consensus Estimate: $-1.97 EPS

Dividends

Dividend History for Aldeyra Therapeutics (NASDAQ:ALDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aldeyra Therapeutics (NASDAQ:ALDX)
Insider Ownership Percentage: 28.40%
Institutional Ownership Percentage: 48.60%
Insider Trades by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)
Institutional Ownership by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)
Insider Trades by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/17/2017Martin Joseph JoyceDirectorBuy4,444$4.50$19,998.00View SEC Filing  
2/17/2017Stephen J TulipanoCFOBuy3,333$4.50$14,998.50View SEC Filing  
2/17/2017Todd C BradyInsiderBuy22,223$4.50$100,003.50View SEC Filing  
2/14/2017Perceptive Advisors LlcMajor ShareholderBuy893,025$4.50$4,018,612.50View SEC Filing  
5/26/2016Perceptive Advisors LlcMajor ShareholderBuy700,000$5.00$3,500,000.00View SEC Filing  
10/26/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.46$323,000.00View SEC Filing  
10/22/2015Perceptive Advisors LlcMajor ShareholderBuy18,020$6.47$116,589.40View SEC Filing  
10/20/2015Perceptive Advisors LlcMajor ShareholderBuy37,145$6.39$237,356.55View SEC Filing  
8/7/2014Martin Joseph JoyceDirectorBuy1,000$3.95$3,950.00View SEC Filing  
8/6/2014C. Boyd ClarkeDirectorBuy3,000$3.69$11,070.00View SEC Filing  
5/7/2014C. Boyd ClarkeDirectorBuy12,500$8.00$100,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Aldeyra Therapeutics (NASDAQ:ALDX)
Latest Headlines for Aldeyra Therapeutics (NASDAQ:ALDX)
Source:
DateHeadline
finance.yahoo.com logoAldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting
finance.yahoo.com - May 17 at 12:31 PM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Announces Earnings Results
www.americanbankingnews.com - May 16 at 12:26 PM
baystreet.ca logoInvestor Network: Aldeyra Therapeutics, Inc. to Host Earnings Call
www.baystreet.ca - May 15 at 3:26 PM
americanbankingnews.com logo-$0.33 Earnings Per Share Expected for Aldeyra Therapeutics Inc (ALDX) This Quarter
www.americanbankingnews.com - May 8 at 12:20 PM
finance.yahoo.com logoAldeyra Therapeutics Schedules Webcast and Conference Call to Provide Corporate Update and First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 11:11 AM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - May 5 at 9:14 PM
americanbankingnews.com logoAldeyra Therapeutics (ALDX) Given Daily Media Sentiment Rating of -0.29
www.americanbankingnews.com - May 2 at 9:24 AM
americanbankingnews.com logoAldeyra Therapeutics (ALDX) Receiving Negative News Coverage, Report Shows
www.americanbankingnews.com - April 28 at 9:00 AM
finance.yahoo.com logoAldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase 3 Clinical Trial
finance.yahoo.com - April 27 at 3:49 PM
americanbankingnews.com logoAldeyra Therapeutics (ALDX) Receives Daily News Impact Rating of 0.44
www.americanbankingnews.com - April 24 at 12:18 PM
streetinsider.com logoAldeyra Therapeutics (ALDX) Confirms FDA Orphan Drug Designation for ADX-102 in Sjögren-Larsson
www.streetinsider.com - April 22 at 10:43 AM
americanbankingnews.com logoPositive Press Coverage Very Unlikely to Affect Aldeyra Therapeutics (ALDX) Stock Price
www.americanbankingnews.com - April 21 at 10:07 AM
finance.yahoo.com logoAldeyra Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-102 in Sjögren-Larsson Syndrome
finance.yahoo.com - April 20 at 3:31 PM
streetinsider.com logoAldeyra Therapeutics (ALDX) Doses Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial
www.streetinsider.com - April 19 at 7:22 AM
finance.yahoo.com logoAldeyra Therapeutics, Inc. Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial
finance.yahoo.com - April 18 at 3:27 PM
americanbankingnews.com logo Brokerages Anticipate Aldeyra Therapeutics Inc (ALDX) to Post -$0.33 Earnings Per Share
www.americanbankingnews.com - April 17 at 11:52 AM
americanbankingnews.com logoAldeyra Therapeutics (ALDX) Given Media Sentiment Rating of 0.28
www.americanbankingnews.com - April 17 at 11:41 AM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Sees Significant Growth in Short Interest
www.americanbankingnews.com - April 8 at 12:50 PM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Earns Buy Rating from Cowen and Company
www.americanbankingnews.com - April 6 at 8:10 AM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Given a $18.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 3 at 12:45 AM
seekingalpha.com logoAldeyra Therapeutics' (ALDX) CEO Todd Brady on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 31 at 3:34 PM
americanbankingnews.com logoCowen and Company Reaffirms "Buy" Rating for Aldeyra Therapeutics Inc (ALDX)
www.americanbankingnews.com - March 31 at 1:43 PM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Earns Buy Rating from Canaccord Genuity
www.americanbankingnews.com - March 31 at 1:43 PM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Releases Earnings Results
www.americanbankingnews.com - March 31 at 10:11 AM
biz.yahoo.com logoQ4 2016 Aldeyra Therapeutics Inc Earnings Release - Before Market Open
biz.yahoo.com - March 30 at 3:51 PM
finance.yahoo.com logoAldeyra Therapeutics Reports Full Year 2016 Financial Results
finance.yahoo.com - March 30 at 3:51 PM
finance.yahoo.com logo8:04 am Aldeyra Therapeutics reports FY16 results
finance.yahoo.com - March 30 at 3:51 PM
biz.yahoo.com logoALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
biz.yahoo.com - March 30 at 3:51 PM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 30 at 9:09 AM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - March 27 at 8:42 PM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - March 24 at 9:44 AM
finance.yahoo.com logoAldeyra Therapeutics Schedules Webcast and Conference Call for Full Year 2016 Financial Results
finance.yahoo.com - March 22 at 3:29 PM
finance.yahoo.com logoAldeyra Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - February 28 at 8:55 AM
finance.yahoo.com logoAldeyra Therapeutics Launches the Aldeyra Registry for Patients with Sjögren-Larsson Syndrome - Yahoo Finance
finance.yahoo.com - February 22 at 3:27 PM
us.rd.yahoo.com logoAldeyra Therapeutics Launches the Aldeyra Registry for Patients with Sjögren-Larsson Syndrome
us.rd.yahoo.com - February 22 at 11:35 AM
us.rd.yahoo.com logoAldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
us.rd.yahoo.com - February 18 at 3:26 PM
finance.yahoo.com logoAldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters ... - Yahoo Finance
finance.yahoo.com - February 18 at 7:59 AM
streetinsider.com logoAldeyra Therapeutics (ALDX) Prices 2.2M Offering of Common Stock at $4.50/Share
www.streetinsider.com - February 14 at 9:06 PM
us.rd.yahoo.com logoAldeyra Therapeutics, Inc. Prices Public Offering of Common Stock
us.rd.yahoo.com - February 14 at 9:06 PM
streetinsider.com logoAldeyra Therapeutics (ALDX) Plans Offering of Common Stock - StreetInsider.com
www.streetinsider.com - February 14 at 4:04 PM
streetinsider.com logoAldeyra Therapeutics (ALDX) Prices 2.2M Offering of Common Stock at $4.50/Share - StreetInsider.com
www.streetinsider.com - February 14 at 4:04 PM
us.rd.yahoo.com logoAldeyra Therapeutics, Inc. Proposes Public Offering of Common Stock
us.rd.yahoo.com - February 13 at 8:55 PM
us.rd.yahoo.com logo4:02 pm Aldeyra Therapeutics commences common stock offering; size not disclosed
us.rd.yahoo.com - February 13 at 8:55 PM
streetinsider.com logoAldeyra Therapeutics (ALDX) Says First Patient Enrolled in Allergic Conjunctivitis Phase 2b Trial of ADX-102 - StreetInsider.com
www.streetinsider.com - February 7 at 3:54 PM
finance.yahoo.com logoAldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 2b Clinical Trial
finance.yahoo.com - February 7 at 3:54 PM
finance.yahoo.com logoAldeyra Therapeutics to Participate at the 2017 Rare Disease, Biopharma One-on-One Day
finance.yahoo.com - February 6 at 3:30 PM
nasdaq.com logoELGX Abuzz, ESPR Ahead Of Schedule, Tough Times For VIVO
www.nasdaq.com - January 26 at 1:37 AM
streetinsider.com logoAldeyra Therapeutics (ALDX) Offers Update on Phase 3 Programs
www.streetinsider.com - January 26 at 1:37 AM
streetinsider.com logoAldeyra Therapeutics (ALDX) Offers Update on Phase 3 Programs - StreetInsider.com
www.streetinsider.com - January 25 at 3:32 PM

Social

Chart

Aldeyra Therapeutics (ALDX) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff